These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24674108)

  • 41. Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.
    Taketomi T; Szlam F; Levy JH; Tanaka KA
    Blood Coagul Fibrinolysis; 2008 Jan; 19(1):106-8. PubMed ID: 18180627
    [No Abstract]   [Full Text] [Related]  

  • 42. Reversal of drug-induced anticoagulation: old solutions and new problems.
    Dzik WS
    Transfusion; 2012 May; 52 Suppl 1():45S-55S. PubMed ID: 22578371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fixed versus variable dose of prothrombin complex concentrate for counteracting vitamin K antagonist therapy.
    Khorsand N; Veeger NJ; Muller M; Overdiek JW; Huisman W; van Hest RM; Meijer K
    Transfus Med; 2011 Apr; 21(2):116-23. PubMed ID: 21073580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.
    Limdi NA; Nolin TD; Booth SL; Centi A; Marques MB; Crowley MR; Allon M; Beasley TM
    Am J Kidney Dis; 2015 May; 65(5):701-9. PubMed ID: 25468385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation.
    Lubetsky A; Shasha Y; Olchovsky D; Loebstein R; Halkin H; Ezra D
    Thromb Haemost; 2003 Jul; 90(1):71-6. PubMed ID: 12876628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Reversal of acenocoumarol anticoagulation with activated factor VII in massive hemorrhage following rupture of a splenic artery pseudoaneurysm].
    Varela CA; Gómez JM; Reina MA; López A; Galindo S; Arruga AM
    Rev Esp Anestesiol Reanim; 2009 Apr; 56(4):245-8. PubMed ID: 19537265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
    Le Roux P; Pollack CV; Milan M; Schaefer A
    J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.
    Yasaka M; Sakata T; Naritomi H; Minematsu K
    Thromb Res; 2005; 115(6):455-9. PubMed ID: 15792675
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.
    Sconce EA; Kamali F
    Eur J Haematol; 2006 Dec; 77(6):457-62. PubMed ID: 17042764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intracerebral hemorrhage in patients receiving oral anticoagulation therapy.
    da Silva IR; Provencio JJ
    J Intensive Care Med; 2015 Feb; 30(2):63-78. PubMed ID: 23753250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis.
    Dezee KJ; Shimeall WT; Douglas KM; Shumway NM; O'malley PG
    Arch Intern Med; 2006 Feb; 166(4):391-7. PubMed ID: 16505257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage.
    Sarode R; Matevosyan K; Bhagat R; Rutherford C; Madden C; Beshay JE
    J Neurosurg; 2012 Mar; 116(3):491-7. PubMed ID: 22175718
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reversal of vitamin K antagonist-associated coagulopathy: a survey of current practice.
    Neal M; Crowther M; Douketis J; Verhovsek M; Stidley C; Garcia D
    Thromb Res; 2008; 122(6):864-6. PubMed ID: 18678398
    [No Abstract]   [Full Text] [Related]  

  • 54. Warfarin use and dose adjustment in a patient with mitral valve replacement.
    Yuan SM
    Pak J Pharm Sci; 2015 Jul; 28(4):1351-5. PubMed ID: 26142525
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The use of recombinant factor VIIa in warfarin patients with traumatic brain injury: a retrospective case-control study.
    DeLoughery EP; Lenfesty B; DeLoughery TG
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):317-20. PubMed ID: 23429251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Warfarin initiation and monitoring with clotting factors II, VII, and X.
    Trask AS; Gosselin RC; Diaz JA; Dager WE
    Ann Pharmacother; 2004 Feb; 38(2):251-6. PubMed ID: 14742761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute overdose: suicide attempt.
    Vyas D; Lackey G; McCulloh RJ
    Simul Healthc; 2013 Aug; 8(4):272-8. PubMed ID: 23912070
    [No Abstract]   [Full Text] [Related]  

  • 58. Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1.
    Shetty HG; Backhouse G; Bentley DP; Routledge PA
    Thromb Haemost; 1992 Jan; 67(1):13-5. PubMed ID: 1615468
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elevated international normalized ratio from vitamin K supplement discontinuation.
    Miesner AR; Sullivan TS
    Ann Pharmacother; 2011 Jan; 45(1):e2. PubMed ID: 21205949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical experience with oral versus intravenous vitamin K for warfarin reversal.
    Meehan R; Tavares M; Sweeney J
    Transfusion; 2013 Mar; 53(3):491-8; quiz 490. PubMed ID: 22738309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.